Evidence map›Paper›PMID 40560500›Full record

ReviewAnnals of surgical oncology2026

Consensus Guideline for the Management of Peritoneal Mesothelioma.

Leanne M Brown, Sarah G Wilkins, Varun V Bansal, David G Su, Jorge Gomez-Mayorga, Kiran K Turaga, Craig G Gunderson, Byrne Lee, Garrett M Nash, John L Hays and 7 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Leanne M BrownYale School of Medicine, New Haven, CT, USA.
Sarah G WilkinsYale School of Medicine, New Haven, CT, USA.
Varun V BansalYale School of Medicine, New Haven, CT, USA.
David G SuYale School of Medicine, New Haven, CT, USA.
Jorge Gomez-MayorgaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Kiran K TuragaYale School of Medicine, New Haven, CT, USA. kiran.turaga@yale.edu.
Craig G GundersonYale School of Medicine, New Haven, CT, USA.
Byrne LeeStanford University School of Medicine, Stanford, CA, USA.
Garrett M NashMemorial Sloan Kettering Cancer Center, New York, NY, USA.
John L HaysThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
Kanwal P RaghavThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aliya L HusainUniversity of Chicago, Chicago, IL, USA.
Michael D KlugerColumbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Marjorie G ZaudererWestchester Medical Center, Hawthorne, NY, USA.
Hedy L KindlerUniversity of Chicago, Chicago, IL, USA.
H Richard AlexanderRutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Peritoneal Surface Malignancies (PSM) Consortium Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of peritoneal mesothelioma (PeM) poses significant challenges owing to its rare incidence, heterogeneity, and limited clinical evidence. This manuscript describes results from a national consensus aimed at addressing management of PeM.

methodsAn update of the 2018 Chicago Consensus Guidelines was conducted using a Modified Delphi technique, encompassing two rounds of voting. The levels of agreement for various pathway blocks were assessed.

resultsOf 101 participants responding in the first round of Modified Delphi voting, 95 (94%) responded in the second round. Over 90% consensus was achieved in 5/6 and 6/6 pathway blocks in rounds I and II, respectively. Observation was recommended for benign neoplasms, with guidance for interventions in the presence of symptoms or concerning clinicopathologic features. For malignant pathology, management was outlined based on a multidisciplinary assessment of patient characteristics, disease histology, and predictive success of medical and surgical interventions. Additional emphasis was placed on multimodal therapy for Intermediate-Risk and appropriate High-Risk patients. A rapid review demonstrated limited availability of data and inconclusive findings regarding optimal systemic therapy timing. There was unanimous support for considering clinical trial enrollment.

conclusionsGiven limited evidence, the consensus-driven pathway provides essential guidance regarding the management of PeM. To further direct clinical care, additional dedicated research to generate higher-quality evidence is needed.

Indexed as

ConsensusMesotheliomaPeritoneal NeoplasmsPractice Guidelines as TopicCombined Modality TherapyDelphi TechniqueDisease ManagementHumansPrognosisCytoreductive surgical proceduresGuidelinesMesotheliomaPeritoneal surface malignanciesPeritoneal surface neoplasms

Identifiers

PMID40560500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.